Drugs / NE-58095 DR
last change Nov 2015 re-read 2 minutes ago

NE-58095 DR

Developed for
osteoporosis
Investigated by
EA Pharma Co., Ltd. · Takeda

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT02063854 Feb 2014 → Nov 2015 osteoporosis Takeda Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NE-58095 DR ClinicalTrials.gov intervention name — accepted as the source's own label NCT02063854
Route Oral “NE-58095 DR 25 mg tablet, orally, once, monthly” NCT02063854